lundi 23 novembre 2015

Onco Actu du 23 novembre 2015

1. Biologie

Tumor-suppressor p53 regulates protein that stifles immune attack on cancer [MD Anderson Cancer Center]

3.1 Tabac

Smokeless tobacco users exposed to more nicotine, cancer-causing chemical [Reuters]

3.4 Chimioprévention

New patent paves way for breast cancer prevention [MedicalXPress]

5. Traitements

Injectable Smart BioGel Destroys Cancer Where it Resides [GEN]

5.10 Traitements - Essais

Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress [Merck]

Updated Data Showed That Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) Helped People With a Specific Type of Advanced Melanoma Live Significantly Longer Than With Zelboraf Alone [Genentech]

Brain Cancer Vaccine Gets Better With Time, as Celldex Shows Survival Edge [Forbes]

Celldex vaccine improves long-term brain cancer survival in study [Reuters]

NovoCure's cancer therapy effective in late-stage study [Reuters]

5.2 Pharma

Roche buoyed by early data on atezolizumab in advanced melanoma [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

Pfizer and Allergan Reach $150 Billion Merger Deal [NY Times]

5.3.4 Traitements - AMM (FDA, EMA)

Takeda's 'breakthrough' Velcade heir wins early FDA approval in myeloma [FierceBiotech]

U.S. FDA Approves Takeda's NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma [Takeda]

FDA approves Ninlaro, new oral medication to treat multiple myeloma [FDA]

Novartis gets FDA approval for skin cancer drug combination [Reuters]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 November 2015 [EMA]

6.10 Politiques

'Orphan Drug' Loophole Needs Closing, Johns Hopkins Researchers Say [Johns Hopkins]